Want to see AZTR full AI Analyst Report?
AZTR Stock Chart & Stats
$0.18
<$0.01(1.03%)
At close: 4:00 PM EDT
$0.18
<$0.01(1.03%)
Day’s Range― - ―
52-Week Range$0.10 - $1.09
Previous Close$0.13
Volume406.85K
Average Volume (3M)2.43M
Market Cap
$10.91M
Enterprise Value-$3.08
Total Cash (Recent Filing)$6.73M
Total Debt (Recent Filing)$410.05K
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Nov 17, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.30
Shares Outstanding60,603,740
10 Day Avg. Volume4,515,598
30 Day Avg. Volume2,434,430
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.34
Price to Sales (P/S)0.00
P/FCF Ratio-0.11
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.25
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Balance-sheet RepairLow debt limits fixed financial obligations and provides greater flexibility to fund development. The move from negative to positive equity indicates balance-sheet repair, although continued losses remain a constraint.
Platform Diversification Into Cosmetics And Biotech ToolsExpanding beyond clinical dermatology creates multiple potential commercialization paths, including cosmetic ingredients, research tools, partnerships, and licensing. This diversification may reduce dependence on one drug candidate over time.
Proprietary Technology And Clinical Development PotentialA sizable microbial library and clinical-site expansion support Azitra’s ability to discover and test differentiated topical biotherapeutics. Successful development could strengthen partnering prospects and create a defensible dermatology pipeline.
Bears Say
Pre-revenue Model With Persistent LossesThe absence of recurring revenue leaves Azitra dependent on financing, grants, or future partnerships to support operations. Persistent losses also show that the platform has not yet translated into commercial scale or operating leverage.
Heavy And Potentially Volatile Cash BurnSustained cash consumption increases the likelihood of additional capital raises before products generate revenue. The extreme TTM figure may reflect data volatility or a one-time movement, but the reported profile still signals material funding risk.
Dilution And Program-prioritization RiskExpanded share capacity improves financing flexibility but creates substantial dilution potential for existing holders. Pausing ATR-12 also narrows near-term pipeline progress and shows that capital constraints are shaping development priorities.
Azitra Inc News
AZTR FAQ
What was Azitra Inc’s price range in the past 12 months?
Azitra Inc lowest stock price was $0.10 and its highest was $1.09 in the past 12 months.
What is Azitra Inc’s market cap?
Azitra Inc’s market cap is $10.91M.
When is Azitra Inc’s upcoming earnings report date?
Azitra Inc’s upcoming earnings report date is Nov 17, 2026 which is in 73 days.
How were Azitra Inc’s earnings last quarter?
Azitra Inc released its earnings results on Aug 12, 2026. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of -$0.115 by -$0.055.
Is Azitra Inc overvalued?
According to Wall Street analysts Azitra Inc’s price is currently Overvalued.
Does Azitra Inc pay dividends?
Azitra Inc does not currently pay dividends.
What is Azitra Inc’s EPS estimate?
Azitra Inc’s EPS estimate is -0.04.
How many shares outstanding does Azitra Inc have?
Azitra Inc has 60,603,740 shares outstanding.
What happened to Azitra Inc’s price movement after its last earnings report?
Azitra Inc reported an EPS of -$0.17 in its last earnings report, missing expectations of -$0.115. Following the earnings report the stock price went up 3.704%.
Which hedge fund is a major shareholder of Azitra Inc?
Currently, no hedge funds are holding shares in AZTR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Azitra Inc
Azitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases. The company's pipeline features several key therapeutic candidates: ATR-12: A genetically modified strain of S. epidermidis intended to treat Netherton syndrome, a specific skin disorder. ATR-04: Another modified S. epidermidis strain, designed to alleviate the papulopustular rash commonly experienced by cancer patients undergoing epidermal growth factor receptor inhibitor therapy. ATR-01: An engineered recombinant human filaggrin protein developed for the treatment of ichthyosis vulgaris, another dermatological ailment. Founded in 2014, Azitra, Inc. operates from its headquarters in Branford, Connecticut.
Technical Analysis
Ownership Overview
27.62% Insiders
0.47% Mutual Funds
69.91% Other Institutional Investors
1.99% Public Companies and
Individual Investors